Takeda forced to withdraw Actos in France
pharmafile | July 11, 2011 | News story | Sales and Marketing | Actos, Competact, Takeda, diabetes
Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country’s medicines regulator.
The Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) last month moved to prevent Actos (pioglitazone), and Takeda’s related brand Competact, from being prescribed by suspending their use.
Now, with an EMA safety review still ongoing, AFSSAPS appears to have decided stronger local measures were necessary and asked for both drugs to be withdrawn altogether in France.
It first acted after a French study of public insurance data confirmed a slight increase in the risk of bladder cancer in patients treated with pioglitazone.
In a statement the company said: “Takeda is confident in the therapeutic benefits of pioglitazone and its importance as a treatment for type II diabetes. We continuously monitor the safety and tolerability of all of our products and will continue to work with the EMA and other individual regulatory bodies to share and review all available data, and to determine appropriate next steps.”
Actos is currently Takeda’s best-selling product, bringing in Y387.9 billion ($4.83 billion) last year, but faces an increasingly uncertain future.
The French study last month persuaded Germany to recommend new patients are not given either Actos (pioglitazone) or Competact (piolglitazone and metformin).
Meanwhile, European regulatory advisers at the CHMP will pronounce on the two drugs’ safety at their next meeting later this month and a US review, though still ongoing, has already led to stronger safety warnings from the FDA.
Dominic Tyer
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
